US FDA urges broader populations in drug studies
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is continuing to urge drug companies to include broad populations in their clinical trials, after an analysis of 147 studies in 42 conditions for applications for new medicines submitted in fiscal year 2010 revealed troubling information about patients being excluded from trials research.